Consensus $431.67M. The company expects to achieve adjusted EBITDA breakeven for the fourth quarter of FY26. The company said, “Total revenue in the range of $435 million to $440 million, growth of 16% at the midpoint, compared to prior guidance of $425 to $435 million. We expect the revenue increase versus prior guidance to be generally balanced across DSPS and NGS. Gross margin to be above 52% for fiscal 2026.”
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Is TWST a Buy, Before Earnings?
- Cathie Wood Doubles Down on Crypto Stocks, Trims Kratos Defense and TWST. Here’s Why
- Cathie Wood Invests Over $3M Into Crypto Stock, Trims Stakes in Kratos Defense and TWST
- Cathie Wood Sells Biotech Stocks, Bets Big on Tempus AI and WeRide
- Twist Bioscience price target raised to $50 from $42 at Guggenheim